Item 1.01 - Entry into a Material Definitive Agreement: Waters Corporation entered into one or more material definitive agreements on or around February 9, 2026 Item 2.01 - Completion of Acquisition or Disposition of Assets: Waters Corporation completed an acquisition or disposition of assets as of the filing date Item 2.03 - Creation of a Direct Financial Obligation: Waters Corporation created…

Our analysis rates this filing BEARISH. Waters Corporation faces a HIGH concern level (7.2/10) driven by the materialization of significant financial and operational risks from the BD Biosciences acquisition. While the transaction closed successfully, the company now carries $4.0B in new debt with…

Concern level: HIGH (7.2/10). Key factors: Four new high-severity risks identified with average severity 6.75/10, including two risks rated 8/10 (Debt Assumption/Leverage and Integration Risk); Significant near-term refinancing risk: $3.5B of $4.0B term loan due in 364 days (February 2027) with no disclosed refinancing plan or alternative liquidity sources; Leverage covenant of 3.50x (expandable…

Notable risk changes: MAJOR: Waters assumed $4.0 billion in term loans with $3.5B due in 364 days, creating significant near-term refinancing risk and materially increasing leverage. Leverage covenant of 3.50x (expandable to 4.25x) indicates tight financial constraints post-acquisition.; MAJOR: Ownership structure fundamentally changed - BD shareholders now own 39.2% of combined company, diluting original Waters…

The model predicts WAT will underperform the S&P 500 by about 0.0% over 30 days. This is model analysis for research, not investment advice.